PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28973643-0	2017	Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology.	Tacrolimus	0-10	activin A receptor, type II-like 1	Mus musculus	78-82	
28973643-4	2017	By screening the NIH clinical collections of FDA-approved drugs, we identified tacrolimus (FK-506) as the most potent activator of ALK1 signaling in BMP9-challenged C2C12 reporter cells.	Tacrolimus	79-89	activin A receptor, type II-like 1	Mus musculus	131-135	
28973643-4	2017	By screening the NIH clinical collections of FDA-approved drugs, we identified tacrolimus (FK-506) as the most potent activator of ALK1 signaling in BMP9-challenged C2C12 reporter cells.	Tacrolimus	91-97	activin A receptor, type II-like 1	Mus musculus	131-135	
28973643-5	2017	In HUVECs, tacrolimus activated Smad1/5/8 and opposed the pro-angiogenic gene expression signature associated with ALK1 loss-of-function, by notably reducing Dll4 expression.	Tacrolimus	11-21	activin A receptor, type II-like 1	Mus musculus	115-119	
28973643-8	2017	Finally, tacrolimus stimulated Smad1/5/8 signaling in C2C12 cells expressing BMP9-unresponsive ALK1 HHT mutants and in HHT patient blood outgrowth ECs.	Tacrolimus	9-19	activin A receptor, type II-like 1	Mus musculus	95-99